Nanjing Tongnuokang Pharmaceutical Technology

Nanjing Tongnuokang Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, dedicated to the discovery and development of innovative small molecule drugs. The company primarily focuses on oncology and autoimmune diseases, utilizing a proprietary structure-based drug design platform to create highly selective kinase inhibitors. Its lead candidate, TNK001, is a next-generation BTK inhibitor currently in Phase 2 clinical trials for B-cell malignancies. Other pipeline programs include selective inhibitors targeting the JAK and TYK2 pathways for various inflammatory conditions. Tongnuokang aims to address significant unmet medical needs by developing potent therapeutics with improved safety profiles compared to existing treatments.